Article
Engineering, Biomedical
Lifo Ruan, Jun Chen, Chuanchao Du, Huiru Lu, Jiayu Zhang, Xiaomeng Cai, Rui Dou, Wenchu Lin, Zhifang Chai, Guangjun Nie, Yi Hu
Summary: The use of mitochondrial temperature-responsive drug delivery system can prevent drug efflux, facilitate drug accumulation and mitochondrial targeting in drug-resistant tumors. This technology enhances drug toxicity and reverses drug resistance, representing a significant advancement in combating cancer drug resistance.
BIOACTIVE MATERIALS
(2022)
Article
Cell Biology
Buse Cevatemre, Engin Ulukaya, Egemen Dere, Sukru Dilege, Ceyda Acilan
Summary: There has been growing interest in the role of mitochondria in metastatic cascade. This study demonstrates that inhibiting PDH can induce EMT and result in chemoresistance.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Mohamed Haider, Amr Elsherbeny, Valeria Pittala, Valeria Consoli, Maha Ali Alghamdi, Zahid Hussain, Ghalia Khoder, Khaled Greish
Summary: Lung cancer is a major cause of cancer occurrence and mortality worldwide. Drug resistance is a complex process in lung cancer, and nanomedicine provides promising tools for reversing resistance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Qian Zhou, Wensheng Chen, Zhenzhen Fan, Zhipeng Chen, Jinxia Liang, Guandi Zeng, Lu Liu, Wanting Liu, Tong Yang, Xin Cao, Biao Yu, Meng Xu, Ye-Guang Chen, Liang Chen
Summary: In this study, MYOCD was identified as a clinically relevant tumor suppressor gene in lung cancer patients, showing a potent inhibitory effect on lung cancer stem cells. NSCLC cells deficient of MYOCD were found to be particularly sensitive to TGFBR kinase inhibitor, and a synergistic effect was observed when combining TGFBRi with stemness inhibitor to treat MYOCD deficient lung cancers.
Article
Multidisciplinary Sciences
Linlin Guo, Atish Mohanty, Sharad Singhal, Saumya Srivastava, Arin Nam, Charles Warden, Sravani Ramisetty, Yate-Ching Yuan, Hyejin Cho, Xiwei Wu, Aimin Li, Manik Vohra, Srinivas Vinod Saladi, Deric Wheeler, Leonidas Arvanitis, Erminia Massarelli, Prakash Kulkarni, Yiming Zeng, Ravi Salgia
Summary: This study investigates the role of ITGB4 and SOX2 in platinum resistance in LUSC. It shows that the expression of SOX2 and ITGB4 is high in all LUSC subtypes, but their impact on patient survival varies. CSCs isolated from LUSC patients are resistant to cisplatin, but knocking down ITGB4 or SOX2 sensitizes them to cisplatin. CFZ synergizes with cisplatin and inhibits CSC growth by inhibiting ITGB4 and SOX2 expression. CFZ also inhibits SOX2 expression epigenetically and suppresses the growth of SOX2-dependent small cell lung cancer cells.
Article
Biochemistry & Molecular Biology
Xuefeng Li, Cheng Li, Chenchen Guo, Qiqi Zhao, Jiayu Cao, Hsin-Yi Huang, Meiting Yue, Yun Xue, Yujuan Jin, Liang Hu, Hongbin Ji
Summary: The heterogeneity of SCLC phenotype is associated with different sensitivity to chemotherapy; activation of the PI3K/Akt/mTOR pathway promotes phenotypic transition and chemo-resistance in SCLC cells; combining chemotherapy with PI3K/Akt/mTOR pathway inhibitors can overcome chemo-resistance in SCLC treatment.
JOURNAL OF GENETICS AND GENOMICS
(2021)
Review
Chemistry, Multidisciplinary
Xiuli Zheng, Xiaohai Song, Guonian Zhu, Dayi Pan, Haonan Li, Jiankun Hu, Kai Xiao, Qiyong Gong, Zhongwei Gu, Kui Luo, Weimin Li
Summary: Lung cancer, the second most prevalent cancer and the leading cause of cancer-related death, is often accompanied by drug resistance. Nanomedicine, with its multifunctional and tunable physiochemical properties, holds great promise in overcoming drug resistance in lung cancer treatment.
ADVANCED MATERIALS
(2023)
Review
Pharmacology & Pharmacy
Hang Yan, Shengjie Tang, Shoujun Tang, Jun Zhang, Haiyang Guo, Chao Qin, Haiyang Hu, Chuan Zhong, Li Yang, Yunhe Zhu, Haining Zhou
Summary: Non-small cell lung cancer (NSCLC) is a common malignant tumor with suboptimal clinical success due to late diagnosis, limited treatment options, high recurrence rates, and drug resistance. MicroRNAs (miRNAs), small non-coding RNAs, have emerged as important players in NSCLC initiation, progression, and drug resistance. This review provides an overview of miRNA dysregulation and resistance in NSCLC and discusses their potential applications in different anti-cancer treatments.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Qizhi Wang, Ming Wu, Haobin Li, Xin Rao, Luyao Ao, Huan Wang, Lan Yao, Xinyu Wang, Xiaodan Hong, Jun Wang, Jiye Aa, Minjie Sun, Guangji Wang, Jiali Liu, Fang Zhou
Summary: This study investigates the common mechanisms of drug resistance and epithelial-mesenchymal transition (EMT) in non-small-cell lung cancer (NSCLC) from the perspective of metabolic reprogramming. It identifies GLUD1 as a key determinant of glutamine addiction in acquired resistant NSCLC cells, and shows that GLUD1-mediated alpha-KG production and ROS accumulation primarily trigger migration and invasion. Pharmacological and genetic interference with GLUD1 reverses drug resistance and decreases cell migration and invasion capability. The successful application of a GLUD1 inhibitor overcomes both acquired resistance and EMT-induced metastasis in vivo, demonstrating GLUD1 as a promising therapeutic target for NSCLC progression.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Elif Erturk, Omer E. Onur, Ipek Aydin, Oguzhan Akgun, Demet Coskun, Ferda Ari
Summary: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with poor overall survival due to EMT feature and metastasis. In this study, we investigated the combination of niclosamide and chalcone complexes targeting the EMT pathway as a potential strategy to enhance antitumor response against NSCLC cells. Our results showed that this combination killed cancer cells more effectively than normal lung cells, and also decreased multidrug resistance and EMT activity.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2023)
Review
Medicine, Research & Experimental
Mahshid Shahverdi, Khalil Hajiasgharzadeh, Amin Daei Sorkhabi, Mahdi Jafarlou, Maryam Shojaee, Neda Jalili Tabrizi, Nazila Alizadeh, Mariacarmela Santarpia, Oronzo Brunetti, Hossein Safarpour, Nicola Silvestris, Behzad Baradaran
Summary: Autophagy plays a crucial role in various diseases, and miRNAs can regulate cellular autophagy activity. Dysfunction of miRNAs is associated with the onset and drug resistance of lung cancer. Studying the interplay between miRNAs, autophagy, and drug resistance in lung cancer can lead to the development of new treatment interventions.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Immunology
Xing-Xing Fan, Qiang Wu
Summary: Lung cancer is highly heterogeneous, and single-cell analysis can help us understand its molecular characteristics and cell types better. Recent findings may provide new directions for the treatment strategies of lung cancer.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Medicinal
Xinyi Wang, Zhikun Liu, Yuanjiang Wang, Shaohua Gou
Summary: In this study, a novel platinum(IV) prodrug was developed to inhibit cancer stem cells and overcome cisplatin resistance in non-small cell lung cancer, demonstrating potent antitumor activity.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Pharmacology & Pharmacy
Junnan Li, Lipeng Zhu, Hang Fai Kwok
Summary: Lung cancer is a highly lethal tumor with poor early diagnosis and emerging drug resistance. Nanomedicine has emerged as a promising tool to revolutionize lung cancer diagnosis and overcome drug resistance.
DRUG RESISTANCE UPDATES
(2023)
Review
Biochemistry & Molecular Biology
Danilo Rocco, Luigi Sapio, Luigi Della Gravara, Silvio Naviglio, Cesare Gridelli
Summary: RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have transformed the treatment landscape for RET-positive (RET+) advanced non-small cell lung cancer (NSCLC) due to their effectiveness and safety profiles. However, there is still limited understanding of resistance mechanisms after treatment with these TKIs. Chemotherapy +/- immunotherapy is currently recommended as a second-line treatment for patients progressing on selpercatinib or pralsetinib. Therefore, further research on the resistance mechanisms triggered by RET-TKIs is crucial.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)